Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma.

Y, Doki; JA, Ajani; K, Kato; J, Xu; L, Wyrwicz; S, Motoyama; T, Ogata; H, Kawakami; CH, Hsu; A, Adenis; Hajbi F, El; Bartolomeo M, Di; MI, Braghiroli; E, Holtved; SA, Ostoich; HR, Kim; M, Ueno; W, Mansoor; WC, Yang; T, Liu; J, Bridgewater; T, Makino; I, Xynos; X, Liu; M, Lei; K, Kondo; A, Patel; J, Gricar; I, Chau; Y, Kitagawa

doi:10.1056/nejmoa2111380

Public

Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma.

Shared by NobleBlocks on Feb 1, 2022 • 12:00 AM UTC

Authors:

Doki Y

Ajani JA

Kato K

Abstract

<h4>Background</h4>First-line chemotherapy for advanced esophageal squamous-cell carcinoma results in poor outcomes. The monoclonal antibody nivolumab has shown an overall survival benefit over chemotherapy in previously treated patients with advanced esophageal squamous-cell carcinoma.<h4>Methods</...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!